行情

CHEK

CHEK

Check Cap
NASDAQ

实时行情|Nasdaq Last Sale

0.8510
+0.0096
+1.14%
盘后: 0.8300 -0.021 -2.47% 16:36 11/26 EST
开盘
0.8200
昨收
0.8414
最高
0.8650
最低
0.8200
成交量
55.00万
成交额
--
52周最高
4.490
52周最低
0.3050
市值
8,204.06万
市盈率(TTM)
-3.5968
分时
5日
1月
3月
1年
5年
BRIEF-Check-Cap Reports Publication Of Peer-Reviewed Article Highlighting Safety And Patient Satisfaction Data For Its Colorectal Screening Test
reuters.com · 5天前
Check-Cap Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for its Colorectal Screening Test, C-Scan®
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before t...
PR Newswire · 5天前
Check-Cap EPS 超出 0.09 美元
Check-Cap (NASDAQ:CHEK): Q3 GAAP EPS of $0.04 beats by $0.09. Cash and cash equivalents, restricted cash and short-term bank deposits as of September 30, 2021 were $56.8 million, compared with
Seekingalpha · 11/03 12:48
BRIEF-Check-Cap Reports Third Quarter 2021 Financial Results And Corporate Update
reuters.com · 11/03 12:45
Check-Cap Q3 EPS $(0.04) Up From $(0.09) YoY
Check-Cap (NASDAQ:CHEK) reported quarterly losses of $(0.04) per share. This is a 55.56 percent increase over losses of $(0.09) per share from the same period last year.
Benzinga · 11/03 12:32
BRIEF-Check-Cap Announces Grant Of Patent Covering C-Scan's Proprietary Tracking Technology In U.S. And Additional Major Market Territories
reuters.com · 11/02 12:43
Check-Cap Announces Grant of Patent Covering C-Scan's Proprietary Tracking Technology in the U.S. and Additional Major Market Territories
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before th...
PR Newswire · 11/02 12:30
Brief-Check-Cap 宣布扩大生产能力和生产线
reuters.com · 10/18 12:10
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CHEK最新的财务预测,通过CHEK每股收益,每股净资产,每股现金流等数据分析Check Cap近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
50.00%买入
50.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CHEK价格均价为2.500,最高价位3.000,最低价为2.000。
最高3.000
均价2.500
最低2.000
现价0.8510
EPS
实际EPS
预期EPS
-0.06-0.04-0.03-0.01
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 37
机构持股: 431.98万
持股比例: 4.48%
总股本: 9,640.49万
类型机构数股数
增持
3
13.64万
建仓
6
320.00万
减持
2
17.59万
平仓
7
377.27万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Chairman/Director
Steven Hanley
Chief Executive Officer
Alex Ovadia
Chief Financial Officer
Mira Rosenzweig
Chief Technology Officer
Yoav Kimchy
Vice President - Operations
Joshua Belkar
Vice President
Hanit Brenner-lavie
Vice President
Israel Hershko
Vice President - Research & Development
Boaz Shpigelman
Independent Director
Clara Ezed
Independent Director
Mary Jo Gorman
Independent Director
XiangQian Lin
Independent Director
Yuval Yanai
暂无数据
CHEK 简况
Check-Cap Ltd.(Check-Cap)是一家临床级医疗诊断公司。该公司从事利用低剂量X射线检测与成像结肠息肉和结肠直肠癌(或CRC)的可摄入成像胶囊的开发业务。该公司的系统由主要部件组成,如可摄取扫描胶囊、胶囊定位系统(CPS)、佩戴在患者背部的记录仪以及用于数据重建和图像处理的个人计算机(PC)工作站。该公司的扫描胶囊通过胃肠道被天然动力吞咽与推进,并被自然排出且无需取回收集数据。该公司的扫描胶囊采用低剂量X射线,即使被肠内容物包围,也允许系统对结肠内衬进行成像。该公司的胶囊将信息传送到佩戴在患者身体上的存储离线分析信息的接收装置。

微牛提供Check Cap Ltd(NASDAQ-CHEK)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CHEK股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CHEK股票基本功能。